Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

计划入组 30 人 · 首次发布于 2023 年 3 月 14 日

Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis

计划入组 2 人 · 首次发布于 2010 年 9 月 22 日

Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada

计划入组 6,000 人 · 首次发布于 2013 年 12 月 12 日

GPR119 agonists (Astellas Pharma)

M3 modulator(Astellas Pharma)

Canada Association

Astellas Pharma Canada, Inc

Canada

ASTELLAS PHARMA

Japan

Astellas Pharma GmbH

Germany

Ontario Expands Public Coverage of XTANDI for High-Risk Prostate Cancer Patients

JAMP Pharma Group Launches Generic Enzalutamide for Prostate Cancer Treatment in Canada

Astellas Withdraws EU Application for Geographic Atrophy Drug Avacincaptad Pegol